BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 8101146)

  • 1. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
    Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
    King CM; Reznek RH; Bomanji J; Ur E; Britton KE; Grossman AB; Besser GM
    Clin Radiol; 1993 Dec; 48(6):386-91. PubMed ID: 8293643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
    Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
    Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
    Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
    Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
    J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
    QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
    Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
    Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary imaging using a labelled somatostatin analogue in acromegaly.
    Ur E; Mather SJ; Bomanji J; Ellison D; Britton KE; Grossman AB; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):147-50. PubMed ID: 1348978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
    Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
    Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
    Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
    Modlin IM; Cornelius E; Lawton GP
    Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
    Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
    Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.